|Full HTA Assessment
|Nilotinib CML resistant/intolerant to imatinib
|For the treatment of chronic phase CML.
|Full submission received from Applicant
|NCPE assessment completed
|NCPE assessment outcome
|Reimbursement not recommended
The cost-effectiveness of nilotinib compared to dasatinib, in patients resistant to imatinib has not been demonstrated.